Protara Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TARA | PRTA | PRQR | CSBR | PLX | PTX.AX | |
|---|---|---|---|---|---|---|
| Market cap | 138.87M | 430.72M | 198.98M | 67.23M | 216.74M | 60.62M |
| P/E (TTM) | — | — | — | — | 11.7 | — |
| Forward P/E | -1.4 | -6.4 | -3.0 | 48.3 | 4.3 | 5.3 |
| Price/book | 0.9 | 1.5 | 2.2 | 17.3 | 3.0 | 3.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −45.72% | −16.77% | −42.44% | −29.80% | +9.66% | +10.87% |
| Today | −2.49% | +2.19% | +2.92% | 0.00% | +3.07% | +3.92% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All TARA news ›Protara Therapeutics (TARA) Set to Announce Earnings on Monday
Posted by Michael Walen on Nov 2nd, 2026 Protara Therapeutics (NASDAQ:TARA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) earnings per share for the quarter, missing…
Protara Therapeutics (NASDAQ:TARA) Stock Price Down 5.3% – Here’s Why
Posted by Kim Johansen on Oct 15th, 2026 Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report)’s share price dropped 5.3% on Wednesday. The stock traded as low as $2.47 and last traded at $2.48. 701,413 shares changed hands during…
Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Protara Therapeutics Completes Enrollment of the Phase 2b GlobeNewswire
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com2
- globenewswire.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.